#1 Clinical Trials Search in Europe

Prasugrel Hydrobromide

This article discusses the use of Prasugrel Hydrobromide, an antiplatelet medication, in clinical trials for patients with Spontaneous Coronary Artery Dissection (SCAD). The BA-SCAD trial aims to assess the effectiveness of medical therapies, including antiplatelet agents like Prasugrel, in managing this rare but serious heart condition. We’ll explore the trial’s objectives, design, and potential implications for SCAD patients.

Table of Contents

What is Prasugrel Hydrobromide?

Prasugrel Hydrobromide, also known simply as Prasugrel, is a medication that belongs to a class of drugs called antiplatelet agents[1]. These medications work by preventing blood platelets from sticking together, which helps to prevent blood clots from forming in your arteries. Prasugrel is marketed under various brand names and is used in the treatment of certain cardiovascular conditions.

Medical Use

Prasugrel is primarily used in the treatment and prevention of cardiovascular diseases. In the context of the clinical trial discussed here, it is being studied for its potential benefits in patients with Spontaneous Coronary Artery Dissection (SCAD)[1]. SCAD is a rare but serious condition where a tear forms in a blood vessel in the heart.

The medication is classified as an antiplatelet agent, which means it helps prevent blood clots from forming in your arteries. This can be crucial for patients at risk of heart attacks or strokes, especially those who have already experienced a cardiovascular event or have undergone certain heart procedures.

Administration

Prasugrel is typically administered orally, meaning it is taken by mouth[1]. This makes it convenient for patients to take at home as prescribed by their healthcare provider.

Dosage

The dosage of Prasugrel can vary depending on the specific condition being treated and individual patient factors. However, in the clinical trial mentioned, the maximum daily dose is reported as 60 mg[1]. It’s important to note that this is a maximum dose used in a controlled study setting, and individual prescriptions may differ. Always follow your doctor’s instructions regarding dosage.

Current Clinical Trial

Prasugrel is currently being studied in a clinical trial called “BA-SCAD” (Beta-Blockers and Antiplatelet Agents in Spontaneous Coronary Artery Dissection)[1]. This trial aims to assess the effectiveness of medical therapy, including antiplatelet agents like Prasugrel, in patients with SCAD. The study is designed to compare different treatment strategies:

  • 1-month single antiplatelet therapy versus 12-month dual antiplatelet therapy[1]

This trial will help researchers understand the best way to use antiplatelet medications like Prasugrel in treating SCAD patients.

Potential Side Effects

While the specific side effects are not detailed in the provided clinical trial information, it’s important to note that all medications can have potential side effects. As an antiplatelet agent, Prasugrel may increase the risk of bleeding. In the clinical trial, bleeding is being monitored as a safety endpoint[1].

Always discuss potential side effects with your healthcare provider before starting any new medication. They can provide you with a comprehensive list of side effects to watch for and advice on how to manage them if they occur.

Aspect Details
Trial Name BA-SCAD (Beta-Blockers and Antiplatelet Agents in Spontaneous Coronary Artery Dissection)
Main Objective Assess efficacy of medical therapy (β-blockers and antiplatelet agents) in SCAD patients
Study Design Randomized controlled pragmatic trial using a 2×2 factorial design
Treatment Arms 1. β-blockers vs No β-blockers
2. 1-month single antiplatelet vs 12-month dual antiplatelet therapy
Primary Endpoint Combined clinical endpoint at 1-year follow-up (death, MI, stroke, coronary revascularization, recurrent dissection, hospital admission for ACS or heart failure)
Prasugrel Hydrobromide Use Antiplatelet agent; max daily dose 60 mg; max treatment period 12 months
Key Inclusion Criteria SCAD diagnosis on coronary angiography during index hospitalization
Key Exclusion Criteria Cardiogenic shock, severe heart disease, limited life expectancy, pregnancy

FAQ

  • What is Spontaneous Coronary Artery Dissection (SCAD)? SCAD is a rare heart condition where a tear forms in a coronary artery wall, causing blood to flow between the layers and potentially leading to a heart attack. It often affects young, otherwise healthy individuals, particularly women.
  • What is the purpose of the BA-SCAD clinical trial? The BA-SCAD trial aims to assess the effectiveness of medical therapies, including beta-blockers and antiplatelet agents like Prasugrel, in patients with Spontaneous Coronary Artery Dissection.
  • How is Prasugrel Hydrobromide used in this trial? Prasugrel Hydrobromide is used as an antiplatelet agent in the trial. Patients are randomized to receive either 1-month single antiplatelet therapy or 12-month dual antiplatelet therapy to evaluate its effectiveness in treating SCAD.
  • What are the main outcomes being measured in this trial? The primary outcome is a combined clinical endpoint including death, heart attack, stroke, coronary revascularization, recurrent dissection, and hospital admission for acute coronary syndrome or heart failure at 1-year follow-up.
  • Who is eligible to participate in this clinical trial? Eligible participants include patients admitted for acute coronary syndrome or any other manifestation of myocardial ischemia, with a diagnosis of SCAD on a coronary angiography during their hospital stay. Patients must provide written informed consent to participate.

Ongoing Clinical Trials on Prasugrel Hydrobromide

  • Study on the Effects of Metoprolol, Prasugrel, and Carbasalate Calcium in Patients with Spontaneous Coronary Artery Dissection

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Spontaneous Coronary Artery Dissection (SCAD): A rare heart condition where a tear forms in the wall of a coronary artery, causing blood to flow between the layers and potentially leading to a heart attack.
  • Prasugrel Hydrobromide: An antiplatelet medication used to prevent blood clots in patients with certain heart conditions.
  • Antiplatelet agent: A type of medication that helps prevent blood clots by stopping blood platelets from sticking together.
  • Beta-blockers: Medications that reduce blood pressure and heart rate by blocking the effects of the hormone epinephrine, also known as adrenaline.
  • Acute Coronary Syndrome (ACS): A term used to describe a range of conditions associated with sudden, reduced blood flow to the heart, including heart attacks and unstable angina.
  • Coronary angiography: A procedure that uses X-ray imaging to examine blood vessels in the heart.
  • Myocardial ischemia: A condition where blood flow to the heart is reduced, preventing it from receiving enough oxygen.
  • Coronary revascularization: A procedure to restore blood flow to the heart muscle by reopening blocked arteries.
  • Cardiogenic shock: A serious condition where the heart suddenly can't pump enough blood to meet the body's needs.
  • BARC definitions: Standardized criteria used to classify and report bleeding events in cardiovascular clinical trials.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-metoprolol-prasugrel-and-carbasalate-calcium-in-patients-with-spontaneous-coronary-artery-dissection/